Company release, 19 October 2023 at 9:00 a.m. (EEST)
Nightingale Health Plc’s Annual Report for financial year 1 July 2022–30 June 2023 has been published. The publication includes the Board of Directors' Report, the Consolidated and Parent Company Financial Statements, the Corporate Governance Statement, and the Remuneration Report.
The Annual Report, the Board of Directors’ Report, the Consolidated and Parent Company Financial Statements, the Corporate Governance Statement, and the Remuneration Report are attached to this release and are also available on Nightingale Health’s website at www.nightingalehealth.com/investors/.
For further information, please contact:
Teemu Suna, CEO
Oaklins Merasco Ltd, tel. +358 9 6129 670
About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
Annual Report 2022–2023
Board of Directors’ Report and Consolidated and Parent Company Financial Statements 2022–2023
Corporate Governance Statement 2022–2023
Remuneration Report 2022–2023